Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Submission Wave Continues; Is A Crest Near?

Executive Summary

Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.

Advertisement

Related Content

Another ANDA Submission Surge Begins
Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I
ANDA Approvals, Complete Responses Hit Record In FY 2016
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
Dark, Then Dawn: ANDA Workload Approaching Steady State After 2014 Eruption
Generic Reviews Steaming Ahead, But Are Storm Clouds On The Horizon?
Review Times Remain A GDUFA II Topic
Generic User Fees: FDA Goes On Backlog Offensive
ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?
GDUFA Performance Goals For Fiscal Years 2013-2017

Topics

Advertisement
UsernamePublicRestriction

Register

PS119660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel